Kornimate/medical-research-clean huggingface dataset:
the relationship between vascular adhesion protein-1 and diabetic cardiovascular autonomic neuropathy

Conditions: Neuropathy; Peripheral, Autonomic, in Diabetes Mellitus (Manifestation)

Summary: exploring the relationship between serum vap-1 and cardiovascular autonomic neuropathy in subjects with type 2 diabetes mellitus

the prevalence of diabetes mellitus is increasing recently, especially in the urban area of developing countries. subjects with diabetes have higher rate of hospitalization and have higher mortality. diabetes results in various complications including diabetic retinopathy, nephropathy, neuropathy, and cardiovascular complications. among these, cardiovascular autonomic neuropathy is one of clinical important complication of diabetes. diabetic subjects with reduced cardiovascular autonomic function have been shown to strongly associate with an increased risk of silent myocardial ischemia and increased mortality. they also have higher risk of sudden death, intraoperative and perioperative cardiovascular instability. formation of advanced glycation end product (age) and oxidative stress are important causes of diabetic neuropathy. vascular adhesion protein-1 (vap-1), an adhesion molecule with an activity of semicarbazide-sensitive amine oxidases (ssao), which can catalyze endogenous amines to produces corresponding aldehydes, h2o2, and ammonia. we have demonstrated that serum vap-1 is a source of systemic age and oxidative stress, and is associated with nephropathy and atherosclerosis. there are reports demonstrating that subjects with diabetic retinopathy or stroke have higher serum vap-1. to our best knowledge, there is no report regarding the relationship between serum vap-1 and neuropathy. in present study, we will measure serum vap-1 and check cardiovascular autonomic function. we will also explore the relationship between serum vap-1 and cardiovascular autonomic neuropathy in subjects with type 2 diabetes mellitus.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus exclusion criteria: * arrythmia

Keywords: diabetes cardiovascular autonomic neuropathy vap 1
an observational real-world study to evaluate the impact of dermatological toxicities on the quality of life in patients with early breast cancer treated with adjuvant endocrine therapy - bcare (breast cancer adjuvant real-world evaluation of dermatological adverse events)

Conditions: Early Breast Cancer; Skin Condition; Quality of Life

Summary: the goal of this european observational study (frane, spain, italy, spain and greece) is to describe the quality of life related to dermatological toxicities, in adult women patients with early breast cancer (ebc), treated with an ongoing adjuvant endocrine monotherapy initiated for 2 to 3 years ago before inclusion in the study. in order to answer these objectives, the patient are completing 4 quality of life questionnaires focussed on dermatological issues (dlqi, skindex-16, hairdex and itchyqol) at the time of the inclusion. early breast cancer (ebc) diagnosis and history, demographics/clinical characteristics, skin care/sun protection care and skin toxicities since start of the adjuvant endocrine therapy will be collected by the investigator in the ecrf.

patients will complete the questionnaires at inclusion using a webbased pro system

Eligibility criteria:
inclusion criteria: 1. females aged ≥ 18 years at inclusion. 2. histologically confirmed diagnosis of ebc, according to the who criteria and the tnm classification, at any time before inclusion. 3. still being treated with adjuvant endocrine monotherapy, initiated 2 to 3 years ago before the inclusion in the study. 4. signed informed consent form (icf) or non-opposition, according to local regulations. exclusion criteria: 1. patients not able to read, understand and complete questionnaires in local language. 2. with chronic dermatological conditions (treated or not) before initiating the adjuvant endocrine therapy that could interfere with the quality of life. 3. patients with concomitant targeted therapies with adjuvant endocrine therapy such as cdk4/6 inhibitors or trastuzumab, and patients with ongoing treatment with neratinib. 4. patients having relevant or severe comorbidities requiring complex therapeutic treatment. 5. patients having a persistent post-chemotherapy alopecia (at least of grade 1)

Keywords: early breast cancer adjuvant endocrine therapy quality of life patient reported outcomes skin toxicities
insul-in this together program for adolescents with type 1 diabetes and their parents

Conditions: Type 1 Diabetes

Summary: the "insul-in this together" intervention is designed for teens with type 1 diabetes and their parents. this study seeks to evaluate an evidence-based family intervention for teens with type 1 diabetes and their parents to offset the psychosocial and diabetes self-management risks. this information will provide a more in-depth understanding of family-based program efficacy for teens with adolescents and provide more judicious and streamlined intervention options to be offered in diabetes clinics in the future.

this study will collect survey and biomedical data to assess this program in a randomized controlled trial with 165 families (including an adolescent and parent/caregiver) will be enrolled, complete surveys, provide biomedical data via continuous glucose monitors and receive a 6-week psychosocial intervention. the results of this study will inform future intervention redesign to provide more judicious interventions to be disseminated across diabetes care.this study will evaluate the relative efficacy of each of the individual intervention components and also identify the mechanisms of actions (mediators) that are most impacted by these types of interventions as well as most linked to long-term outcomes for adolescents.

Eligibility criteria:
inclusion criteria: 1. teen subject has a type 1 diabetes (t1d) diagnosis according to ada criteria for at least 6 months 2. teen subject is age 12-19 years at time of screening (no age limit for parent participants) 3. participation of at least one cohabitating parent/caregiver. exclusion criteria: 1. subject lacks access to a smartphone or wi-fi via computer 2. subject has restricted or no english proficiency 3. subject has a pervasive developmental, cognitive, or psychiatric limitations that compromise participation in study
evaluation of the effect of tms on primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: based on the pain threshold and visual simulation score, primary dysmenorrhea patients will be divided into treatment effective group or non-effective group.according to the functional magnetic resonance imaging, the investigators investigate whether there is characteristic or secondary brain features before and after rtms intervention.

long term primary dysmenorrhea may induce a series of disorders involving psychology, lower quality of life, or even developing chronic organic lesion or chronic pain. effective symptom improvement is urgently needed. during the non-pharmaceutical interventions, repetitive transcranial magnetic stimulation (rtms) is received preliminary approval because of its noninvasive and safe analgesic effect. in this randomized single blind longitudinal study, the investigators investigate the analgesic effect of rtms in long term moderate-to-severe primary dysmenorrhea women. based on the pain threshold and visual simulation score, primary dysmenorrhea patients will be divided into treatment effective group or non-effective group. according to the functional magnetic resonance imaging, the investigators investigate whether there is characteristic or secondary brain features before and after rtms intervention. by combining pre and post performances of the degree of dysmenorrhea, behavioral data and sensitive hematological indicators, the investigators intend to build an association model between brain and pain development curve. using correlation and multiple regression analysis method, the investigators intend to find sensitive neuroimaging biomarkers in predicting the analgesic effect of rtms. the current study is not only contributing to improve the central nervous systematic mechanism of rtms in chronic pelvic pain, but also significant for clinical effective treatment based on neuroimaging predictive markers.

Eligibility criteria:
inclusion criteria: * consistent with the diagnostic criteria for primary dysmenorrhea according to the american college of obstetricians and gynecologists; * regular menstrual cycles (27-32 days); * the average intensity of dysmenorrhoeic pain in the past 6 months should be rated ≥4 on a visual analogue scale (vas) (0 = no pain, 10 = the worst imaginable pain). exclusion criteria: * organic pelvic disease; * using oral contraceptives, hormonal supplements, chinese traditional medicine or any central-acting medication (e.g., opioids, anti-epileptics) within 6 months before the study; * comorbid chronic pain states; * alcohol, nicotine or drug addiction; * neurologic disease or psychiatric disorder; * history of childbirth; * a positive pregnancy test or immediate plans for pregnancy; * any mri contraindications. in addition, no analgesics were consumed 24 hours prior to the experiment.

Keywords: rtms primary dysmenorrhea
pilates versus eccentric exercises on multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this study aims to determine whether pilates-based stability or eccentric training is more effective for patients with multiple sclerosis(ms) with chronic non-specific low back pain(nslbp).

thirty adult patients with multiple sclerosis with chronic nslbp verified diagnosis of ms by a specialized neurologist will be questioned and screened according to inclusion and exclusion criteria. patients were randomly allocated to one of two groups: (pilates or eccentric). every individual in both groups will be examined before and after the 6-week treatment program. the handheld dynamometer assessed isometric trunk flexion and extension strength pain intensity by casual analog scale (vas). the trunk impairment scale (tis) evaluates static and dynamic sitting balance and trunk coordination in a seated position.

Eligibility criteria:
inclusion criteria: * age range 18 to 40 years. * relapsing-remitting free for at least 90 days before testing. exclusion criteria: * having a neurologic disease other than ms. * a relapse within 3 months.

Keywords: pilates eccentric multiple sclerosis low back pain
montelukast in chronic asthma

Conditions: Asthma

Summary: treatment of patients insufficiently treated with ics or ics + laba.


Eligibility criteria:
inclusion criteria: * patients insufficiently treated with ics or ics + laba.
a study of asct bridging cart cell therapy in relapsed/refractory b-cell lymphoma

Conditions: Relapsed Non Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma

Summary: this is a single center, prospective cohort study to to evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation(asct) bridging chimeric antigen receptor t (cart) cell therapy in the treatment of relapsed/refractory b-cell non-hodgkin's lymphoma.

high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation(asct) is still the standard salvage treatment for relapsed/refractory b-cell non-hodgkin's lymphoma (r/r b-nhl). however, its overall survival (os) and event-free survival (efs) of 3 years and above are less than 50%. chimeric antigen receptor t (cart) cell therapy has shown great efficacy in treating b-nhl in recent years. preclinical studies have indicated that the infusion of hematopoietic stem cells could promote the amplification and function of adoptive metastatic anti-tumor cd8+t cells, providing a certain theoretical basis for asct combined with cart cell therapy. in order to evaluate the efficacy and safety of asct bridging cart cell therapy in treating r/r b-nhl, we conduct this single center, prospective cohort study.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed b-nhl with extrinsic involvement. 2. age ≥ 18 years and ≤ 65 years. 3. measurable disease of at least 15mm(node)/10mm（extranodal） 4. meet any of the following conditions :1. after 4 courses of standard first-line treatment or 2 courses of treatment with more than two lines, the lesions decreased by less than 50%;2 b-nhl with disease progression after first-line or induction treatment;3. relapsed b-nhl within 12 months after asct;4. after standard chemotherapy or hematopoietic stem cell transplantation, the size of any new lesions or the previously involved site which had achieved complete remission increased by 50% or more. 5. receive standard autologous hematopoietic stem cell transplantation with cd34+ cells ≥2\*10\^6/kg. 6. estimated survival time ≥3 months exclusion criteria: 1. having received allogeneic hematopoietic stem cell transplantation previously; 2. hiv-positive; 3. active hepatitis b or c infection; 4. previous history of other malignant tumors. excluded: patients who had cured basal or squamous cell carcinoma of the skin and carcinoma in situ of the cervix at any time prior to the study; patients with disease-free survival ≥5 years who had been cured by surgery only without further treatment for the other tumors listed above can be included in the study. 5. patients with cardiac insufficiency:ejection fraction (ef) \< 30%, nyha standard, grade ii or above 6. patients with liver and renal insufficiency: serum direct bilirubin (sb) ≥2mg/ dl (34.2μmol/l), aspartate aminotransferase(ast) \> 2.5 times the up, serum creatinine (scr) \> 2.5mg/ dl (221μmol/l) 7. female patients who are pregnant, preparing to become pregnant or lactating. 8. the investigator believes that there are other factors that are not suitable for inclusion or affect subjects' participation or completion of the study.
effects on insulin resistance with tadalafil in type 2 diabetes - a double-blind, placebo-controlled crossover study

Conditions: Diabetes Mellitus, Type 2

Summary: the aim is to continue our program on pde5 inhibition by evaluating effects on insulin resistance, including glucose metabolism and subclinical inflammation, after a 6-week administration of tadalafil in t2d patients. the primary objective is to study the effect of tadalafil compared with placebo on insulin sensitivity during a euglycemic hyperinsulinemic clamp. this is a double-blind, placebo-controlled crossover study with one study site. twenty-five t2d patients will be recruited and randomized to per oral intake of tadalafil 20 mg o.d. for six weeks and after a wash-out period of eight weeks intake of placebo for another six weeks, or vice versa. at the end of each 6 week treatment period a glucose clamp, subcutaneous needle biopsies as well as muscle and subcutaneous microdialysis will be performed. endothelial function tests and arginin stimulation of insulin secretion tests will be performed after 3 weeks in each treatment arm.


Eligibility criteria:
inclusion criteria: 1. t2d patient, previously diagnosed by fasting or 2-hr ogtt plasma glucose levels 2. age females: 55-70 yrs (post-menopausal state defined as natural amenorrhea for at least 12 months); age males: 40-70 yrs 3. bmi: 27-40 kg/m2 4. hba1c \< 60 mmol/mol 5. type 2 diabetes duration \> 3 months and \< 10 yrs 6. understand and speak swedish exclusion criteria: 1. diabetes treatment with glitazones, glp-1 analogues or dpp-iv inhibitors 2. anti-hypertensive therapy with beta-blockers, ace-inhibitors and/or angiotensin-ii receptor blockers 3. significant microvascular complications e.g. nephropathy (gfr\<60), proliferative retinopathy and symptomatic neuropathy e.g. postural hypotension 4. previous significant vascular disease including angina pectoris and myocardial infarction, cerebral artery disease e.g. history of transient ischemic attacks and peripheral artery disease with no palpable pulses 5. smoking \> 10 cig/day and/or smokeless tobacco \> one can per 2 days 6. concurrent use of nitrates or no donors, or an apparent risk that there may be a need of such medication 7. cardiac failure (stages nyha ii-iv) 8. uncontrolled hypertension \> 170/105 mm hg 9. apparent ecg-pathology indicating current or previous myocardial ischemia; 10. males with erectile dysfunction 11. hemophilia or a history of bruises or hepatic failure (\> 2-fold increase upper limit normal values of asat/alat) 12. hypotension 13. treatment with doxazosin 14. anything in the contact with the patient that makes the doctor to believe that he/she will be uncompliant to the protocol.
effect of drug therapy on reinfarction risk in women

Conditions: Cardiovascular Diseases; Myocardial Infarction; Heart Diseases

Summary: to evaluate the safety of calcium-channel blockers in the secondary prevention of myocardial infarction in women.

background: research on heart disease in the 196os and 197os was primarily concerned with risk factors for 'premature' atherosclerosis, which was most dramatically apparent in working middle-aged men who suffered heart attacks or died suddenly. this focus on 'premature' disease was an important initial step, but it resulted in a relative neglect of studies in older adults and in all women. coronary heart disease remains nonetheless a major cause of morbidity and mortality among women. given the consistent findings from clinical trials that calcium-channel blockers administered following myocardial infarction do not decrease the risk of death or reinfarction, and that some drugs of this class may actually increase the risk, it is unlikely that future trials of this therapy in women will be conducted. yet the calcium-channel blockers are used with increasing frequency in women following myocardial infarction. the only ethical method of conducting studies of the safety of these drugs in women is through observational studies. data from the study can help to guide clinical practice and can assist in the design of appropriate secondary prevention trials in women. design narrative: on-going studies of hormone-replacement therapy in women at group health cooperative of puget sound (ghc) identified all female enrollees who suffered a first heart attack since 1986; the study expanded this inception cohort through 1996. information from medical record review and ghc databases were used to assess risk factors and co-morbid conditions, both at entry into the cohort and up to ten years of follow-up, and to identify recurrent cardiovascular events and deaths. a complete record of prescription drug exposure during the follow-up period was obtained for each subject from the ghc computerized pharmacy database. although the main hypothesis related to reinfarction risk in women, men were studied as well to facilitate comparison of the results of this observational study with those of the clinical trials. according to conservative estimates of the available sample size, the investigators had 86 percent power to detect a relative risk of 1.45 in women alone, and 85 percent power to detect a relative risk of 1.25 in men and women combined, for the association of calcium-channel blocker use with fatal or non-fatal reinfarction. the study also examined the safety and efficacy of other cardiovascular drugs commonly used in women after myocardial infarction, including angiotensin converting-enzyme inhibitors, lipid-lowering drugs, and estrogen replacement therapy.

Eligibility criteria:
no eligibility criteria
study of cardiac lesions angiogenesis by 68ga-nodaga-rgd cardiac pet

Conditions: Myocardial Infarction, Acute; Myocardial Reperfusion; Chronic Ischemic Heart Disease

Summary: the study is about exploring physiological angiogenesis linked to tissue repair in patients with acute heart infarction or chronic heart ischemia by means of 68ga-nodaga-rgd pet/ct imaging.

several animal studies have demonstrated the expression of αvβ3 integrins on the surface of the endothelium present in neovessels in formation, especially during neoangiogenesis after myocardial ischemic injury. 68ga-nodaga-rgd is a positron-emission-tomography (pet) ligand targeted towards αvβ3 integrins. αvβ3 integrins could potentially act as a biomarker for the follow-up of heart infarction. in the present study, 68ga-nodaga-rgd pet/ct imaging is a tool to understand and evaluate tissue repair after heart lesion and its evolution allowing a better management of patients with occluded artery. three groups of patients are included : patients with acute infarction, patients with acute infarction requiring reperfusion treatment and patients with chronic ischemic occlusion. each patient would benefit from a 82rb (82rubidium) pet/ct as part of standard management and from a 68ga-nodaga-rgd pet/ct as part of the present study. patients from groups 1 and 2 will have 3 sets of both exams : one after the ischemic event, one at one month and another at 3 months post event. patients form group 3 will have a set of both exams before reperfusion treatment and one at 2 months after reperfusion.

Eligibility criteria:
inclusion criteria: * patients with acute infarction or patients with acute infarction requiring reperfusion treatment or patients with chronic ischemic occlusion * karnofsky ≥ 80% * signed informed consent exclusion criteria: * pregnancy, breastfeeding * claustrophobia * contra-indication to adenosine administration * lack of discernment to sign informed consent

Keywords: acute myocardial infarction myocardial reperfusion treatment chronic ischemic occlusion 68ga-nodaga-rgd
intervention of shoulder blood flow restriction training on shoulder joint pain and function of judo athletes

Conditions: Shoulder Dislocation; Blood Flow Restriction Training

Summary: to observe the effect of shoulder low load blood flow restriction training on pain, function, strength and joint motion of the subjects with shoulder joint dysfunction.


Eligibility criteria:
inclusion criteria: * ① judo athletes, aged 18-30 years old; ② can cooperate with rehabilitation physiotherapy and training and follow-up, and will not quit the study without reason; the presence of shoulder joint pain and dysfunction; after passing the shoulder function test screening, there are two or more positive tests exclusion criteria: * external injuries of shoulder joint, including bumps, blows, cuts, burns, contusions, etc., without skin rupture, external blood or subcutaneous bleeding; ② congenital abnormal bone structure; ③ there is inflammation, dislocation of shoulder joint, ligament injury; ④ a history of shoulder joint related surgery within one year; ⑤ injury or discomfort to other body parts;
a prospective observational study of sepsis

Conditions: Sepsis

Summary: sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection and is associated with high morbidity and mortality. sepsis3 gives sepsis a broad definition, reflecting the heterogeneity of the disease. so we need a precise treatment with a stratification of patient prognosis in order to reduce mortality in patients with sepsis.


Eligibility criteria:
inclusion criteria: * patients who met the sepsis3 diagnostic criteria. exclusion criteria: * absence of laboratory test items (blood routine examination, coagulation function, liver function, biochemistry, urine routine examination, urine renal function, urine protein, etc.) \>20%. * admission in icu less than 48 hours. * patient with psychiatric disorders. * under 18 years of age.